137 related articles for article (PubMed ID: 30763203)
1. Consecutive Emergence of Typical Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in a Patient With Metastatic Pulmonary Squamous Cell Carcinoma.
Yang CY; Hsieh MS; Liao WY; Shih JY; Yu CJ
J Oncol Pract; 2019 Feb; 15(2):115-118. PubMed ID: 30763203
[No Abstract] [Full Text] [Related]
2. De novo MET amplification promotes intrinsic resistance to first-generation EGFR tyrosine kinase inhibitors.
Li JW; Cao SH; Xu JL; Zhong H
Cancer Biol Ther; 2019; 20(9):1183-1186. PubMed ID: 31131689
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors.
Westover D; Zugazagoitia J; Cho BC; Lovly CM; Paz-Ares L
Ann Oncol; 2018 Jan; 29(suppl_1):i10-i19. PubMed ID: 29462254
[TBL] [Abstract][Full Text] [Related]
4. [Resistant mechanism and treatment strategy of tyrosine kinase inhibitors].
Qiao J; Chen W
Zhongguo Fei Ai Za Zhi; 2011 Oct; 14(10):806-10. PubMed ID: 22008111
[No Abstract] [Full Text] [Related]
5. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
Marquez-Medina D; Popat S
Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
[TBL] [Abstract][Full Text] [Related]
6. Combining inhibitors of ALK and ROS1 with other agents for the treatment of non-small cell lung cancer.
Shaw AT
Clin Adv Hematol Oncol; 2015 May; 13(5):282-4. PubMed ID: 26352769
[No Abstract] [Full Text] [Related]
7. [EGFR tyrosine kinase inhibitors in lung cancer management: sensitivity and resistance].
Moldvay J; Peták I
Magy Onkol; 2012 Mar; 56(1):38-49. PubMed ID: 22403761
[TBL] [Abstract][Full Text] [Related]
8. There is still a role for cytology in the 'liquid biopsy' era. A lesson from a TKI-treated patient showing adenocarcinoma to squamous cell carcinoma transition during disease progression.
Clery E; Pisapia P; Feliciano S; Vigliar E; Marano A; De Luca C; Malapelle U; Troncone G; Bellevicine C
J Clin Pathol; 2017 Sep; 70(9):798-802. PubMed ID: 28363898
[TBL] [Abstract][Full Text] [Related]
9. The immune profile of EGFR-mutated non-small-cell lung cancer at disease onset and progression after tyrosine kinase inhibitors therapy.
Fumagalli C; Guerini-Rocco E; Vacirca D; Passaro A; Marinis F; Barberis M
Immunotherapy; 2018 Sep; 10(12):1041-1045. PubMed ID: 30185137
[No Abstract] [Full Text] [Related]
10. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
Gainor JF; Shaw AT; Sequist LV; Fu X; Azzoli CG; Piotrowska Z; Huynh TG; Zhao L; Fulton L; Schultz KR; Howe E; Farago AF; Sullivan RJ; Stone JR; Digumarthy S; Moran T; Hata AN; Yagi Y; Yeap BY; Engelman JA; Mino-Kenudson M
Clin Cancer Res; 2016 Sep; 22(18):4585-93. PubMed ID: 27225694
[TBL] [Abstract][Full Text] [Related]
11. Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study).
Hata A; Katakami N; Kaji R; Yokoyama T; Kaneda T; Tamiya M; Inoue T; Kimura H; Yano Y; Tamura D; Morita S; Negoro S; The Hanshin Oncology Group F
Cancer; 2018 Oct; 124(19):3830-3838. PubMed ID: 30192383
[TBL] [Abstract][Full Text] [Related]
12. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.
Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
Yang Z; Zhang SL; Hu X; Tam KY
Eur J Pharmacol; 2018 Nov; 838():41-52. PubMed ID: 30213498
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy.
Kanda S; Horinouchi H; Fujiwara Y; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Kubota K; Tamura T; Ohe Y
Lung Cancer; 2015 Sep; 89(3):287-93. PubMed ID: 26169499
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase inhibition of EGFR: a successful history of targeted therapy for NSCLC since 20 years.
Vansteenkiste J; Wauters E
Ann Oncol; 2018 Jan; 29(suppl_1):i1-i2. PubMed ID: 29462258
[No Abstract] [Full Text] [Related]
16. Irreversible EGFR inhibitors in the treatment of advanced NSCLC.
Maione P; Rossi A; Bareschino M; Sacco PC; Schettino C; Casaluce F; Sgambato A; Gridelli C
Curr Pharm Des; 2014; 20(24):3894-900. PubMed ID: 24138713
[TBL] [Abstract][Full Text] [Related]
17. Four generations of EGFR TKIs associated with different pathogenic mutations in non-small cell lung carcinoma.
Li R; Zhou X; Yao H; Li L
J Drug Target; 2020 Nov; 28(9):861-872. PubMed ID: 32118494
[TBL] [Abstract][Full Text] [Related]
18. [Molecular Mechanism and Progression of Primary Resistance to EGFR-TKI
- Analysis of 2 Cases].
Liu M; Meng F; Ma Q; Gu L; Zhong D
Zhongguo Fei Ai Za Zhi; 2019 Jan; 22(1):52-56. PubMed ID: 30674394
[TBL] [Abstract][Full Text] [Related]
19. EGFR-TK1-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients with NSCLC: When Is it Worth The Risk?
Mormile R
Pathol Oncol Res; 2019 Oct; 25(4):1665-1666. PubMed ID: 30661223
[No Abstract] [Full Text] [Related]
20. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]